Assessment of Third Generation Cephalosporin (Ceftazidime and Ceftriaxone) Resistant Escherichia Coli Strains Isolated from Zahedan Hospitals by Tracing the TEM Gene by Jahani, Somaye et al.
Journal of Applied Biotechnology Reports 
 
Original Article  
Journal of Applied Biotechnology Reports, Volume 4, Issue 1, Winter 2017; 547-552 
 
All rights reserved for official publication of Baqiyatallah university of medical sciences© 
  
Assessment of Third Generation Cephalosporin (Ceftazidime and Ceftriaxone) Resistant  
Escherichia Coli Strains Isolated from Zahedan Hospitals by Tracing the TEM Gene  






Increased use of antibiotics and the tendency of individuals 
to arbitrarily consuming antibiotics have caused pathogen-
ic organisms use of defense mechanisms to be adapted to 
antibiotics and in this way the bacterial resistance to anti-
biotic has emerged. Bacterial resistance against antibiotics 
is gradually increasing, so that it is now regarded as one of 
the challenges and concerns of microbiologists [1]. Me-
chanisms of bacterial resistance to antibiotics are various, 
complex and different for each antibiotic. In some cases 
the resistance is created by chromosome and in other cases 
this is related to the extra-chromosomal DNA, such as 
plasmids. One of these mechanisms is the ability to  
express extended-spectrum beta-lactamase (ESBL) pro-
ducing enzymes in bacteria [2-4]. Extended Spectrum  
Beta-lactamase group of enzymes have the ability to hy-
drolyze oxyimino-beta-lactam and has been found in most 
of the members of the Enterobacteriaceae, including E. 
coli [3]. ESBLs give the property to the bacteria to be re-
sistant not only to penicillin, aztreonam, and cephalospo-
rins, but to other antibiotics, such as aminoglycosides, tri-
methoprim, sulfamethoxazole, and quinolones [5]. Beta-
lactamase enzymes are divided into four classes: A, B, C, 
and D. ESBLs are in group A that are able to hydrolyze 
penicillin, aztreonam, and cephalosporins [6]. Unique be-
ta-lactamase is growing significantly. Transferable plas-
mids acquire genes encoding lactamase enzymes and are 
transferred among bacteria, such as Escherichia coli and 
Klebsiella that do not these enzymes as a chromosomal 
gene [7]. The prevalence of ESBLs-producing strains 
among clinical isolates has increased steadily in recent 
years, which has led some restrictions in antibiotic therapy 
options. Organisms that cause urinary tract infection (UTI-
causing microorganisms), especially E. coli strains, are 
capable of producing large-scale of ESBLs [8]. Two main 
dericatives of TEM-type beta-lactamases are TEM-1 and 
TEM-2. TEM-1 was first isolated in 1965 from an E. coli 
strain isolated from the patient named Temoneria, so it was 
named TEM. TEM transfer to other bacteria is dependent 
on plasmids and transposons. TEM-1 is able to hydrolyze 
ampicillin at a higher rate than carbenicillin, oxacillin, or 
cephalothin and is inhibited by clavulanic acid. However, 
the number of TEM beta-lactamase mutants have been 
found which are capable of hydrolyzing third generation of 
cephalosporins and yet  are resistant to beta-lactamase in-
hibitors and are identified as Inhibitor Resistant TEM 
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(IRT) [9]. Worldwide, Escherichia coli is considered as an 
important Gram-negative bacilli in urinary tract infections 
[10]. Widespread of Escherichia coli resistant strains in 
hospitals across the world, being awareness of their preva-
lence in each district and hospital is necessary for planning 
of experimental treatment policy. Knowing the patterns of 
antibiotic resistance in bacterial populations helps to guide 
the rational use of antibiotics and lead to prevent the fur-
ther spread of resistant strains [11]. The routine examina-
tions, which are performed in clinical laboratories for anti-
biotic susceptibility testing, cannot identify beta-
lactamase-producing strains. Sometimes resistant isolates 
are wrongly reported susceptible to broad-spectrum anti-
biotics, such as cefotaxime, ceftazidime and ceftriaxone 
[10]. Since the interpretation criteria of Clinical and La-
boratory Standards Institute (CLSI) for resistance thre-
shold of Enterobacteriaceae against third-generation ce-
phalosporins is changing, it is recommended to replace 
results of the resistance to cephalosporins that are reported 
on the basis of minimum inhibitory concentrations (MIC) 
 instead of the negative or positive resistance by antibiotic 
discs, regardless of whether ESBLs-producing isolates 
[12]. 
The purpose of this study is to determine the antibiotic 
susceptibility pattern of ESBL-producing E. coli by tracing 
the blaTEM gene in clinical samples. 
 
Materials and Methods 
In this empirical study, from 2015 to 2016, 200 strains of 
Escherichia coli from various clinical specimens, such as 
wound, blood, secretions, urine, etc. were collected from 
three hospitals in Zahedan (Imam Ali, Bu Ali, and Nabie 
Akram), and confirmed by biochemical tests. Antibiotic 
susceptibility was determined by disk diffusion method 
(Kirby-Bauer) according to the recommendations of CLSI, 
for seven antibiotic: ceftriaxone (CRO), ceftazidime 
(CAZ), cefotaxime (CTX), gentamicin (GM), cefepime 
(CPM), ciprofloxacin (CIP), piperacillin (PIP), and imipe-
nem (IMP). All antibiotic discs and powders were pur-
chased from MAST Group Ltd (mastdiscsTM. AST, UK). 
Determination of antibiotic resistance patterns of isolated 
samples by disk diffusion method (Kirby-Bauer) 
According to the CLSI protocol suspension of bacterial 
colonies dissolve in the 2 ml sterile saline solution and 
then the 0.5 McFarland turbidity standard was provided. 
The suspension compared with control tube (0.5 McFar-
land) and turbidity was the same for both tubes. Then, near 
the flame, bacterial suspensions (1X10
6 bacteria) were cul-
tured densely on Mueller-Hinton (MHA) agar medium so 
that the entire surface of plate was smeared (a lawn culture 
of the isolated bacteria on Mueller-Hinton agar was made). 
The antibiotic discs were placed on the medium by sterile 
forceps 2 cm from the plate wall and with 25 mm apart 
[13]. Isolates that have reduced susceptibility to ceftazi-
dime and ceftriaxone were studied using confirmatory test 
for ESBL production by the combination disk method. 
Through the combination of the discs, ceftazidime (30 μg) 
and ceftazidime (30 μg) in combination with clavulanic 
acid (10 μg), ceftriaxone (30 μg), and ceftriaxone (30 μg) 
in combination with clavulanic acid (10 μg) was used. The 
results were interpreted according to CLSI recommenda-
tions. Therefore, if inhibition zone diameter of the combi-
nation discs be equal with inhibition zone diameter of the 
disc alone (A ≥ 5 mm) is considered ESBL positive. E. coli 
ATCC 25922 strain was used as positive control and Kleb-
siella pneumoniae ATCC 700603 was used as negative 
control [14].  
After incubation at 37°C for 16-18 hours, beta-lactamase-
producing strains by an increase of  ≥5 mm in zone of in-
hibition for ceftazidime + clavulanic acid compared to 
ceftazidime alone and ceftriaxone + clavulanic acid com-
pared to ceftriaxone alone was confirmed as ESBL produc-
ing strains, according to the recommendations of CLSI 
(2011). 
Broth dilution method to determine the minimum inhibi-
tory concentrations (MIC) 
Broth dilution method was used to determine the minimum 
inhibitory concentrations (MIC) of ceftazidime and cef-
triaxone. Pure antibiotic powders were prepared. Proper 
solvents for each antibiotic powder were selected, sodium 
bicarbonate solution for ceftazidime and distilled water for 
ceftriaxone.  
To prepare serial dilutions of antibiotics, at first 128 µl of 
antibiotic stock with the concentration of 10 mg/ml added 
to a tube and 872 µl of sterile Mueller-Hinton broth me-
dium was added to this tube to make the concentration of 
1280 µg/ml of the relevant antibiotic. Then, 125 µl of tube 
A was poured into tube B and 875 µl of sterile Mueller - 
Hinton broth medium was added to this tube to make 160 
μg/ml dilution. In the next step 125 µl solution of tube B 
was poured into tube C and 875 µl of sterile Mueller-
Hinton broth medium was added to this tube to obtain 20 
μg/ml concentration of the antibiotics. Then, antibiotic 
dilutions in tubes A, B, and C are used to prepare serial 
dilutions for MIC test. To perform the test, concentration 
of 0.25 to 512 μg per ml of each antibiotic was prepared. 
Genetic studies 
After performing the phenotypic tests (disk diffusion and 
MIC) and identification of resistant and ESBLs-producing 
bacteria, resistant isolates were selected for DNA extrac-
tion. Boiling method was used for DNA extraction (Petit et 
al., 2004). To confirm the presence of isolated DNA, sam-
ples were electrophoresed on a 1% agarose gel and for 
determination of DNA concentration, UV spectrophotome-
ter was used, n which the used wavelength was 260 nm 
and OD value was read up to 1-1.5. PCR assay was per-
formed to investigate the pesence of lactamase gene (bla-
TEM) with 848 bp .The PCR reaction conditions were as 
Table 1. The sequence of the exploited primers was as 
follows: 
Forward primer: 5'GAGTATTCAACATTTCCGTGTC3' 
Reverse primer: 5'TAATCAGTGAGGCACCTATCTC3' 
 
 
100 bp Ladder (Thermo scientific, USA) was used to con-
firm the molecular weight of the PCR products. Gel  
electrophoresis of PCR products was performed on a 1.5 % 
agarose gel. After the electrophoresis, power supply shut 
down and gel removed from the tank and placed carefully 
inside the gel documentation unit and after adjusting and 
sharpening, the image of the gel was photographed. 
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Of the 200 E. coli strains isolated from clinical samples168 
samples were isolated from urine, 17 samples from 
wounds, 12 samples from blood, 2 samples from abscess, 
and 1 sample from ascitic fluid. Antibiotic resistance pat-
tern of isolated clinical strains was as follows: cefotaxime 
66%, ceftazidime 65.5%, ciprofloxacin 62.5%, ceftriaxone 
60.5%, gentamicin 36.5%, and cefepime 36%, while none 
of the isolates showed resistance to imipenem. Among the 
131 samples which were resistant to ceftazidime, 114 
samples were isolated from urine, 9 samples from wound, 
7 samples from blood, and one sample from ascitic fluid. 
Of the 121 samples that were resistant to ceftriaxone, 103 
samples isolated from urine, 11 samples from wounds, 6 
samples from blood, and one sample from the abscess (Ta-
ble 2). 
 
Table 2. Antibiotic resistance pattern of clinical strains of E. coli 
by disk diffusion method. 
 Antibiotic 
The percentage of (%) 
Resistant Intermediate Susceptible 
1 Ceftazidime 65.5 9 25.5 
2 Ceftriaxone 60.5 7 32 
3 Cefotaxime 66 9.5 23.5 
4 Cefepime 36 10 54 
5 Gentamicin 36.5 12.5 51 
6 Ciprofloxacin 62.5 5 32.5 
7 Imipenem 0 0 100 
 
In the combination disk method, an increase of ≥ 5 mm in 
the zone of inhibition for ceftazidime + clavulanic acid and 
ceftriaxone + clavulanic acid indicates ESBL-producing 
strains. In this test 97 strains (47%) were ESBL-producing 
strains. The results of the minimum inhibitory concentra-
tions (MIC) tests are shown in Table 3. 
 
Discussion 
Urinary tract infections that are caused by Escherichia coli 
have a widespread distribution worldwide. It is noticeable 
that E. coli strains are of highly resistance to various anti-
biotics and apparently seem that this resistance level is 
increasing rapidly. 
 
Table 3. Results of the minimum inhibitory concentration of 
resistant strains to ceftazidime and ceftriaxone. 
 
It also indicated that the 72 isolates (38.55 %) were posi-
tive for the blaTEM gene. Image of TEM amplification is 



















Figure 1. PCR results of E. coli strains; line 1: The positive con-
trol; Lines 2-4 and 6-9: Clinical samples; Line 5: 100 bp Ladder . 
 
The important factor in the development of bacterial  
resistance is the production of beta-lactamase enzymes   by 
bacteria. Increase in nosocomial infections and in severe 
cases mortality of them is outcome of such resistance [8]. 
Most of the samples obtained from hospital infections are 
resistant to numerous antibiotics. In the present study, 
nearly 70% of clinical isolates were resistant to third   gen-
eration cephalosporin antibiotics such as ceftazidime and 
ceftriaxone. Most resistant clinical samples are originated 
from hospitals. Broad-spectrum cephalosporins resistance 
in Escherichia coli and Klebsiella pneumoniae is due to 
production of ESBLs that can hydrolyze monobactams and 
cephalosporins [15]. 
Time Temperature (°C) Steps of PCR 
5 min 94 Initial denaturation 
30 s 94 Denaturation 
30 s 60 Annealing 
50 s 72 Extension 
5 min 72 Final extension 
 30 Cycle number 
No. of strains resistant 
to ceftriaxone (CRO) 
No. of strains resistant to 
ceftazidime (CAZ) 
MIC 
5 15  2 μg/ml 
23 13  4  μg/ml 
33 10 8  μg/ml 
16 8 16  μg/ml 
17 13 32  μg/ml 
10 17 64  μg/ml 
10 29 128  μg/ml 
5 21 256  μg/ml 
2 4 512  μg/ml 
848 bp fragment of 
blaTEM gene
1     2    3    4     5    6    7    8  9 
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Phenotypic methods are useful screening method for dis-
tinguishing between ESBL-producing strains and non–
ESBL-producing strains that use other mechanisms for 
resistance to beta-lactam antibiotics [16]. An enzymatic 
mechanism of resistance by ESBL-producing bacteria in 
combination with defects in outer membrane permeability 
and efflux complicates the interpretation of antibiotic re-
sistance of bacteria. Since it is possible that treatment with 
third-generation cephalosporins or aztreonam may lead to 
failure report of strains resistant to these antibiotics is es-
sential. Furthermore, the detection of ESBLs-producing 
strains helps to prevent cross-transmission of such strains 
among patients [16]. 
The increasing resistance in Gram-negative bacilli has 
caused problems in the empirical antibiotic therapy in the 
world. Asia has a long history of ESBL-producing bacte-
ria. Also It is well established that there are many differ-
ences in the prevalence and genetic of ESBLs in hospitals 
and especially in different countries [17]. This was con-
firmed in our study. So when we compared our phenotypic 
tests with other Colleagues who had done similar tests, we 
found that the prevalence of ESBLs-producing organisms 
dramatically increases day by day [18]. 
In a study conducted in India, the incidence of infection 
with ESBL-producing E. coli was reported 79%. In the 
present study, the incidence of infection with ESBL-
producing E. coli was reported 56%. Meanwhile, it has 
been reported that the production of ESBLs in Japan, 
Thailand, Singapore, and Philippines is more than 20% 
and even in some centers its incidence has increased to 
more than 60%. The same data were previously seen in 
South American [19]. ESBLs production rate in Asia is 
varied in different countries. In a phenotyping study in 
India, the prevalence of ESBL-producing E. coli isolates, 
was reported  46.51% [20]. In Taiwan, the prevalence of 
ESBL-producing E. coli isolates was reported  1.5-16.7%  
[21]. In a study in Pakistan, the prevalence of ESBL-
producing E. coli isolates, was reported  41%  [22]. 
In another study in Pakistan, the prevalence of ESBL-
producing E. coli isolates, was reported  56.9 % [23]. Re-
port of ESBLs produced by Escherichia coli in various 
parts of Iran is different (8.9-67%) [24]. In a study con-
ducted by Fazly and colleagues in Mashhad, the preva-
lence of ESBL-producing E. coli isolates was reported 
57.5% [24]. 
In a study by Hoban et al., it was confirmed that E. coli 
strains have remained as important gram negative bacilli in 
urinary tract infections worldwide [10]. Previous studies 
have proven that the prevalence of resistant pathogenic E. 
coli in both inpatient and outpatient [25]. 
Studies in which antibiotic resistance phenotype and MIC 
values were close to values in the current study, are as fol-
lows: Nasa and colleagues in a study in 2011 in Delhi 
showed that the rate of ESBL-producing E. coli was 71.8  
% [25]. Bertrand and colleagues reported the rate of  
ceftriaxone resistance in the Middle East is less than  
values   in our study (42.5%). However, the value of MIC 
was similar (128 µg/ml) [26]. In a study conducted in 2009 
in Tehran, 59.2% of the E. coli isolates were ESBLs-
producing. 29.8% of ESBLs-producing isolates had the 
MIC equal to 128 µg/ml that was the most common MIC 
[27]. In our study also the most common MIC was 128  
µg/ml. 
In a study conducted by Mirzaei and colleagues the rate of 
third-generation cephalosporin resistance (ceftazidime, 
cefotaxime, cefepime) was 56.69% and the most common 
MIC for ceftazidime was obtained 256 µg/ml [28]. In other 
studies, significant differences founded in the rates of re-
sistant bacteria than the present study that can be caused 
by indiscriminate use of ceftriaxone and ceftazidime in the 
region. For example, the ceftazidime resistance rate in the 
study conducted by Hoban et al., was 14.3% vs. 65%, 
which are very different. This value is for listed worldwide 
isolates. In this study, the presence of ESBL for the Middle 
East has been reported 16.2 %. Although the production of 
ESBL indicates resistant to third-generation cephalospo-
rins, other factors, such as changes in membrane proteins 
(including PBP2A) are effective on the cephalosporins 
resistance rate. A study was conducted by Okesola in Ni-
geria, the rate of resistance to ceftriaxone and ceftazidime 
has been reported, 37.5% and 43.4%, respectively (by disc 
diffusion method) [29], whereas in our study the rate of 
resistance to ceftriaxone and ceftazidime were 65.5% and 
61%, respectively  
In another study was conducted by Thean in Singapore, 
until 2009 the value of ceftriaxone resistance rate that was 
obtained by disc diffusion method, increased to 21.7% 
[30], whereas in the present study, the rate of resistance to 
ceftriaxone were reported 61%. The data of the present 
study in comparison to the results of these studies indicates 
1.5-3 fold increase. 
Lactamase gene that is specifically responsible for antibi-
otic resistance in our study is the TEM. However, beta-
lactamase enzyme types and changes in membrane pro-
teins, such as PBP2A involved in antibiotic resistance  
isolates. Our molecular studies revealed that 60%of 
ESBLs-producing E. coli contained TEM gene, whereas in 
a study conducted in 2007, 85.6% of ESBLs-producing 
strains contained TEM gene. Its prevalence is higher than 
in our study. In another study in Turkey, 32.6% of ESBLs-
producing  strains contained TEM gene [31] that preva-
lence of TEM beta-lactamase enzyme in this study was 
lower than in our study. 
In a study conducted in 2011 in Tehran, 128 isolates (64%) 
were ESBLs-producing isolates, which 74 of them (57.8%) 
contained TEM gene [32]. Thus, the prevalence of TEM 
gene in this study was close to our study. 
In another study conducted in Tehran, of 59.2% of E. coli 
isolates that were ESBLS-producing, 46.4% contained 
TEM gene [27]. Thus the prevalence of TEM gene in this 
study was also close to our study. 
 
Conclusion 
ESBLs production should be considered as a major threat 
for consumption of broad-spectrum cephalosporins. To-
day, we are faced with increasing prevalence of ESBL-
producing strains. The results of the present study indicate 
high rates of antimicrobial resistance among Escherichia 
coli strains isolated from this region to ceftriaxone and 
ceftazidime that there is a significant difference between 
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results of this study and results of studies in other parts of 
the world and even some studies of the Middle East and 
Iran. These results were predictable due to the high rate of 
prescribing these two antibiotics. Many clinical laborato-
ries are not aware of the importance and the methods of 
diagnosis of ESBLs and they have not new strategy to pre-
vent the spread of this resistance mechanism. These rea-
sons are  responsible for the lack of an appropriate re-
sponse to stop the global spread of beta-lactamase-
producing bacteria [29]. Therefore, it is recommended for 
the treatment of bacterial infections, at first, beta-lactam 
susceptibility pattern be determined accurately by labora-
tory professionals, then a beta-lactam in combination with 
beta-lactamase inhibitor be used. Accordingly the spread 
of ESBLs among different strains of bacteria is reduced 
[30]. 
Distribution, abundance and diversity of minimum inhibi-
tory concentrations were obtained from the study of this 
population implicitly suggest that E. coli isolates produce 
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